Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deoxycholic acid - Kythera Biopharmaceuticals

Drug Profile

Deoxycholic acid - Kythera Biopharmaceuticals

Alternative Names: ATX-101-Kythera; Belkyra; Kybella; Sodium deoxycholate; Sodium desoxycholate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kythera Biopharmaceuticals
  • Developer Bayer Dermatology; Kythera Biopharmaceuticals
  • Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
  • Mechanism of Action Cell membrane modulators; Membrane lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Subcutaneous fat disorders
  • No development reported Lipoma

Most Recent Events

  • 24 Sep 2021 Launched for Subcutaneous fat disorders in Sweden, United Kingdom, Spain, Denmark, New Zealand, Switzerland, Netherlands, Norway, Norway, Poland, Czech Republic, Hungary, Finland, Hong Kong, Australia, Brazil, Canada (SC) before September 2021
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 12 Dec 2018 Registered for Subcutaneous fat disorders in United Kingdom, Slovenia, Slovakia, Slovakia, Poland, Spain, Denmark, Switzerland, Finland, Netherlands, Czech Republic, Cyprus, Belgium (SC), Portugal (SC), Greece, Italy, Luxembourg, Malta, Ireland, Germany (SC), France (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top